ANTIMICROBIAL RESISTANCE OF SHIGELLA ISOLATES IN BANGLADESH, 1983-1990 - INCREASING FREQUENCY OF STRAINS MULTIPLY RESISTANT TO AMPICILLIN, TRIMETHOPRIM-SULFAMETHOXAZOLE, AND NALIDIXIC-ACID
ANTIMICROBIAL RESISTANCE OF SHIGELLA ISOLATES IN BANGLADESH, 1983-1990 - INCREASING FREQUENCY OF STRAINS MULTIPLY RESISTANT TO AMPICILLIN, TRIMETHOPRIM-SULFAMETHOXAZOLE, AND NALIDIXIC-ACID
复制标题
DOI：
10.1093/clinids/14.5.1055
复制
发表时间：
1992-05-01
影响因子：
11.8
通讯作者：
RONSMANS, C
中科院分区：
文献类型：
--
作者：
BENNISH, ML;SALAM, MA;RONSMANS, C
从1983年至1990年从孟加拉国达卡的一个治疗中心的病人中获得的15，824株志贺菌和从1988年至1990年在社区调查中获得的520株志贺菌对氨苄西林和甲氧苄啶-磺胺甲恶唑（TMP-SMZ）的敏感性进行了测定。测定了1985年后获得的分离株对萘啶酸的敏感性。1983年，13%的分离株对氨苄青霉素耐药，23.5%对TMP-SMZ耐药，0.8%对两种药物耐药。到1990年，在腹泻治疗中心获得的分离株中，51.2%对氨苄青霉素耐药，47.7%对TMP-SMZ耐药，40.5%对两种药物耐药（与1983年的数字相比，P <0.001）。萘啶酸耐药率从1986年的0.8%上升到1990年的20.2%（P <0.001）。1990年，71.5%的志贺菌对氨苄西林耐药，68.5%的志贺菌对TMP-SMZ耐药，67.7%的志贺菌对两种药物耐药，57.9%的志贺菌对萘啶酸耐药。社区监测期间获得的菌株的耐药模式与治疗中心的菌株相似。在孟加拉国，氨苄青霉素和TMP-SMZ不再用于治疗任何种类的志贺氏菌感染，萘二甲酸不再用于治疗由志贺氏菌引起的感染。紫茎泽兰1型
The susceptibility to ampicillin and trimethoprim-sulfamethoxazole (TMP-SMZ) was determined for 15,824 isolates of Shigella obtained from patients attending a treatment center in Dhaka, Bangladesh, from 1983 through 1990 and for 520 isolates obtained during community surveys from 1988 through 1990. Susceptibility to nalidixic acid was determined for isolates obtained after 1985. In 1983 13% of isolates were resistant to ampicillin, 23.5% to TMP-SMZ, and 0.8% to both drugs. By 1990 51.2% of isolates obtained at the Diarrhea Treatment Centre were resistant to ampicillin, 47.7% to TMP-SMZ, and 40.5% to both drugs (for comparison with figures for 1983, P < .001). Resistance to nalidixic acid increased from 0.8% in 1986 to 20.2% in 1990 (P < .001). In 1990 71.5% of Shigella dysenteriae type 1 isolates were resistant to ampicillin, 68.5% to TMP-SMZ, 67.7% to both drugs, and 57.9% to nalidixic acid. The resistance pattern of isolates obtained during community surveillance was similar to that of Treatment Centre isolates. In Bangladesh ampicillin and TMP-SMZ are no longer useful for treatment of infection with any species of Shigella, and nalidixic acid is no longer useful for treatment of infections due to S. dysenteriae type 1.